Amarin Corp Plc (AMRN)

[ziploc_1]

If the dilemma surrounding Vascepa patent infringement by generic Vascepa could be successfully put to rest, I believe that a larger study than the small Brave study would be promptly initiated by either Amarin or by a BP to test Vascepa's efficacy in ameliorating the AD problem, which is crippling millions of Americans' lives and those of their families.